453 related articles for article (PubMed ID: 10466636)
1. A phase I/II study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours.
Habib NA; Hodgson HJ; Lemoine N; Pignatelli M
Hum Gene Ther; 1999 Aug; 10(12):2019-34. PubMed ID: 10466636
[TBL] [Abstract][Full Text] [Related]
2. Biological activities of a recombinant adenovirus p53 (SCH 58500) administered by hepatic arterial infusion in a Phase 1 colorectal cancer trial.
Atencio IA; Grace M; Bordens R; Fritz M; Horowitz JA; Hutchins B; Indelicato S; Jacobs S; Kolz K; Maneval D; Musco ML; Shinoda J; Venook A; Wen S; Warren R
Cancer Gene Ther; 2006 Feb; 13(2):169-81. PubMed ID: 16082381
[TBL] [Abstract][Full Text] [Related]
3. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
4. Recombinant E1-deleted adenovirus-mediated gene therapy for cancer: efficacy studies with p53 tumor suppressor gene and liver histology in tumor xenograft models.
Nielsen LL; Gurnani M; Syed J; Dell J; Hartman B; Cartwright M; Johnson RC
Hum Gene Ther; 1998 Mar; 9(5):681-94. PubMed ID: 9551616
[TBL] [Abstract][Full Text] [Related]
5. Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.
Warren RS; Kirn DH
Surg Oncol Clin N Am; 2002 Jul; 11(3):571-88, vi. PubMed ID: 12487057
[TBL] [Abstract][Full Text] [Related]
6. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
Benjamin R; Helman L; Meyers P; Reaman G
Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
[TBL] [Abstract][Full Text] [Related]
7. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Schuler M; Rochlitz C; Horowitz JA; Schlegel J; Perruchoud AP; Kommoss F; Bolliger CT; Kauczor HU; Dalquen P; Fritz MA; Swanson S; Herrmann R; Huber C
Hum Gene Ther; 1998 Sep; 9(14):2075-82. PubMed ID: 9759934
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
Horowitz J
Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
[TBL] [Abstract][Full Text] [Related]
10. Intra-arterial delivery of a recombinant adenovirus does not increase gene transfer to tumor cells in a rat model of metastatic colorectal carcinoma.
Maron DJ; Tada H; Moscioni AD; Tazelaar J; Fraker DL; Wilson JM; Spitz FR
Mol Ther; 2001 Jul; 4(1):29-35. PubMed ID: 11472103
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer.
Wills KN; Maneval DC; Menzel P; Harris MP; Sutjipto S; Vaillancourt MT; Huang WM; Johnson DE; Anderson SC; Wen SF
Hum Gene Ther; 1994 Sep; 5(9):1079-88. PubMed ID: 7833367
[TBL] [Abstract][Full Text] [Related]
12. Tumour-specific therapeutic adenovirus vectors: repression of transgene expression in healthy cells by endogenous p53.
Lipinski KS; Djeha AH; Krausz E; Lane DP; Searle PF; Mountain A; Wrighton CJ
Gene Ther; 2001 Feb; 8(4):274-81. PubMed ID: 11313801
[TBL] [Abstract][Full Text] [Related]
13. p53 adenoviral vector (Ad-CMV-p53) induced prostatic growth inhibition of primary cultures of human prostate and an experimental rat model.
Shirakawa T; Gotoh A; Gardner TA; Kao C; Zhang ZJ; Matsubara S; Wada Y; Hinata N; Fujisawa M; Hanioka K; Matsuo M; Kamidono S
J Gene Med; 2000; 2(6):426-32. PubMed ID: 11199263
[TBL] [Abstract][Full Text] [Related]
14. In vivo studies of adenovirus-based p53 gene therapy for ovarian cancer.
von Gruenigen VE; Santoso JT; Coleman RL; Muller CY; Miller DS; Mathis JM
Gynecol Oncol; 1998 Jun; 69(3):197-204. PubMed ID: 9648587
[TBL] [Abstract][Full Text] [Related]
15. Adenovirus-mediated p53 gene therapy in pediatric soft-tissue sarcoma cell lines: sensitization to cisplatin and doxorubicin.
Ganjavi H; Gee M; Narendran A; Freedman MH; Malkin D
Cancer Gene Ther; 2005 Apr; 12(4):397-406. PubMed ID: 15618970
[TBL] [Abstract][Full Text] [Related]
16. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Reid T; Galanis E; Abbruzzese J; Sze D; Andrews J; Romel L; Hatfield M; Rubin J; Kirn D
Gene Ther; 2001 Nov; 8(21):1618-26. PubMed ID: 11895000
[TBL] [Abstract][Full Text] [Related]
17. p53 gene therapy in a rat model of hepatocellular carcinoma: intra-arterial delivery of a recombinant adenovirus.
Anderson SC; Johnson DE; Harris MP; Engler H; Hancock W; Huang WM; Wills KN; Gregory RJ; Sutjipto S; Wen SF; Lofgren S; Shepard HM; Maneval DC
Clin Cancer Res; 1998 Jul; 4(7):1649-59. PubMed ID: 9676839
[TBL] [Abstract][Full Text] [Related]
18. Melanoma differentiation associated gene-7, mda-7/IL-24, selectively induces growth suppression, apoptosis and radiosensitization in malignant gliomas in a p53-independent manner.
Su ZZ; Lebedeva IV; Sarkar D; Gopalkrishnan RV; Sauane M; Sigmon C; Yacoub A; Valerie K; Dent P; Fisher PB
Oncogene; 2003 Feb; 22(8):1164-80. PubMed ID: 12606943
[TBL] [Abstract][Full Text] [Related]
19. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.
Spitz FR; Nguyen D; Skibber JM; Cusack J; Roth JA; Cristiano RJ
Anticancer Res; 1996; 16(6B):3415-22. PubMed ID: 9042200
[TBL] [Abstract][Full Text] [Related]
20. Multiple hepatic arterial injections of recombinant adenovirus p53 and 5-fluorouracil after transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a pilot phase II trial.
Tian G; Liu J; Zhou JS; Chen W
Anticancer Drugs; 2009 Jun; 20(5):389-95. PubMed ID: 19287305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
